Dashboard
Manage Tickers

REGN


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-neutral-on-regeneron-pharmaceuticals-maintains-1015-price-target
Cantor Fitzgerald Reiterates Neutral on Re...
09/16/2024 16:59:25

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $101...

Core News & Articles
Regeneron Pharmaceuticals And Sanofi Annou...
09/13/2024 16:17:13

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Curre...

Core News & Articles
Health Canada Has Issued A Notice Of Compl...
09/12/2024 11:38:25

This approval expands the initial Health Canada Notice of Compliance for eosinophilic esophagitis in May 2023 for patients aged...

competitor-analysis-evaluating-regeneron-pharmaceuticals-and-competitors-in-biotechnology-industry
Competitor Analysis: Evaluating Regeneron ...
09/11/2024 15:00:25

sanofi-regeneron-drug-dupixent-shows-successful-treatment-of-patients-with-inflammatory-skin-disease
Sanofi, Regeneron Drug Dupixent Shows Succ...
09/11/2024 13:35:15

Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.

regeneron-pharmaceuticals-announced-new-analyses-of-eylea-hd-aflibercept-injection-8-mg-and-eylea-injection-2-mg-will-be-presented-at-the-annual-meeting-of-the-european-society-of-retina-specialists
Regeneron Pharmaceuticals Announced New An...
09/11/2024 11:04:06

Among the presentation highlights are several new post-hoc analyses of the pivotal PULSAR trial for EYLEA HD in wet age-related...

Core News & Articles
Regeneron And Sanofi's Dupixent (Dupilumab...
09/11/2024 05:44:55

Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoin...

Core News & Articles
Regeneron And Sanofi's Dupixent Becomes Fi...
09/11/2024 05:31:16

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients ach...

1000-invested-in-this-stock-5-years-ago-would-be-worth-4000-today
$1000 Invested In This Stock 5 Years Ago W...
09/10/2024 16:30:23

Core News & Articles
Pooled Analysis From Sanofi's BOREAS And N...
09/10/2024 10:55:53

The results were presented today, in collaboration with Regeneron, for the first time at the 2024 European Respiratory Society ...

regeneron-reports-five-year-results-from-final-pre-specified-overall-survival-analysis-of-phase-3-empower-lung-1-trial-says-results-showcase-durable-survival-benefit-and-impressive-efficacy
Regeneron Reports Five-year Results From F...
09/09/2024 21:05:47

Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and d...

cantor-fitzgerald-reiterates-neutral-on-regeneron-pharmaceuticals-maintains-1015-price-target
Cantor Fitzgerald Reiterates Neutral on Re...
09/09/2024 16:06:39

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $101...

beyond-the-numbers-20-analysts-discuss-regeneron-pharmaceuticals-stock
Beyond The Numbers: 20 Analysts Discuss Re...
09/09/2024 14:00:28

rbc-capital-maintains-outperform-on-regeneron-pharmaceuticals-raises-price-target-to-1282
RBC Capital Maintains Outperform on Regene...
09/09/2024 13:57:15

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price ...

rbc-capital-reiterates-outperform-on-regeneron-pharmaceuticals-maintains-1250-price-target
RBC Capital Reiterates Outperform on Regen...
09/05/2024 16:36:02

RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and maintains $1250 ...

evaluating-regeneron-pharmaceuticals-against-peers-in-biotechnology-industry
Evaluating Regeneron Pharmaceuticals Again...
08/27/2024 15:00:33

regeneron-says-european-commission-has-approved-ordspono-to-treat-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-or-rr-diffuse-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapy
Regeneron Says European Commission Has App...
08/26/2024 11:09:03

This marks the first regulatory approval of Ordspono in the world for these patients. Ordspono is a bispecific antibody that ac...

regeneron-highlights-scientific-innovation-and-leadership-in-respiratory-disease-management-at-ers-2024-featuring-dupixent-and-itepekimab
Regeneron Highlights Scientific Innovation...
08/26/2024 05:48:23

20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), ...

what-analysts-are-saying-about-regeneron-pharmaceuticals-stock
What Analysts Are Saying About Regeneron P...
08/23/2024 15:00:19

piper-sandler-maintains-overweight-on-regeneron-pharmaceuticals-raises-price-target-to-1242
Piper Sandler Maintains Overweight on Rege...
08/23/2024 14:26:11

Piper Sandler analyst Christopher Raymond maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION